Uncovering a Novel Therapeutic Target to Reduce Dementia Risk in Parkinson's Disease

The present study is a proof-of-concept clinical trial to test the efficacy of low doses of a repurposed anti-epileptic drug (levetiracetam) in treating memory problems in Parkinson's disease (PD). Neuroimaging techniques will be used to determine the effect of the drug on specific brain regions (hippocampal subfields). Finally, baseline brain activity of PD patients with memory problems will be compared to PD patients without memory problems and healthy older adults to determine if activity in specific brain regions (hippocampal subfields) can be used to predict memory problems in PD. This information will be useful for future clinical trials to target drugs to these brain regions.

NCT Number	NCT04643327
Lead Sponsor	The University of Queensland Collaborators: Queensland University of Technology, Johns Hopkins University, Cleveland Clinic Lou Ruvo Center for Brain Health, Royal Brisbane and Women's Hospital
Conditions	Parkinson Disease, Mild Cognitive Impairment, Memory Impairment
Enrollment	28 participants
Start Date	2021-02-09
Primary Completion	2025-01 (estimated)
Study Completion	2025-12 (estimated)
Updated on ClinicalTrials.gov	2024-09-25